CCL22 and esophageal squamous cell carcinoma: We depleted DGKα in KYSE410 and KYSE510 cells using shRNA and then treated these ESCC cells with CCL22 (50 ng/ml) to observe the activation of intratumoral FAK and AKT (Figs. 6B, C).